Abstract:BackgroundCancer survivors experience on average a 20% reduction in peak exercise capacity (VO2 peak) post-cancer treatment. Intermuscular fat (IMF) is a strong predictor of reduced exercise capacity in heart failure (HF) patients; however it is unknown whether increased IMF is related to reduced VO2 peak in cancer survivors.Methods and resultsTwenty eight individuals: 14 cancer survivors > 12-months post-cancer treatment and 14 individuals without cancer were matched on age, gender, and body mass index (BMI). Participants underwent magnetic resonance imaging (MRI) assessments of IMF within the paraspinal muscles, VO2 peak and exercise-associated measures of left ventricular ejection fraction (LVEF). Blinded analyses were performed. Associations between the ratio of IMF to skeletal muscle (SM) were estimated using Pearson’s partial correlation coefficients. Individuals with cancer and non-cancer comparators were of similar age (54 ± 17 versus 54 ± 15 years; p = 1.0), gender (5 men and 9 women, both groups), and BMI (27 ± 4 versus 26 ± 4; p = 0.57). Peak VO2 was 22% lower in cancer survivors versus non-cancer comparators (26.9 vs 34.3 ml/kg/min; p = 0.005), and was correlated with IMF:SM in both cancer survivors and non-cancer individuals after accounting for exercise-associated LVEF, resting LVEF, BMI, other body fat depots, and cardiovascular disease (CVD) co-morbidities (p < 0.001 to 0.08 for all adjusted correlations).ConclusionAmong cancer survivors that previously received anthracyclines, increased intermuscular fat is associated with reduced VO2 peak even after accounting for exercise-associated cardiac function. This suggests IMF is important in the development of exercise intolerance, an outcome experienced by a large number of cancer survivors.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the relationship between intermuscular fat (IMF) and the decline in exercise capacity of cancer survivors. Specifically, the study aims to evaluate whether the increase in the proportion of intermuscular fat in survivors after cancer treatment is related to the decrease in peak exercise capacity (VO₂ peak). Through this study, the author hopes to understand the role of intermuscular fat in the decline of exercise endurance of cancer survivors, so as to provide a basis for further research and potential treatment interventions. ### Research Background - **Decline in exercise capacity of cancer survivors**: The average peak exercise capacity (VO₂ peak) of survivors after cancer treatment decreases by about 20%. - **Influence of intermuscular fat**: In patients with heart failure, intermuscular fat is a strong indicator for predicting the decline in exercise capacity, but its role in cancer survivors is still unclear. ### Research Methods - **Participants**: The study included 14 cancer survivors and 14 non - cancer control groups, and the two groups were matched in terms of age, gender and body mass index (BMI). - **Evaluation methods**: - Magnetic resonance imaging (MRI) was used to evaluate the intermuscular fat (IMF) and skeletal muscle (SM) in the paravertebral muscles of the lumbar spine. - Peak exercise capacity (VO₂ peak) and other exercise - related left ventricular ejection fraction (LVEF) were measured. - **Statistical analysis**: Pearson partial correlation coefficient was used to evaluate the association between the ratio of intermuscular fat to skeletal muscle (IMF:SM) and peak exercise capacity, and other possible confounding factors such as resting LVEF, exercise - related LVEF, BMI, other fat depots and cardiovascular disease (CVD) comorbidities were adjusted. ### Main Findings - **Differences in exercise capacity**: The peak exercise capacity of cancer survivors was significantly lower than that of the non - cancer control group (26.9 vs 34.3 ml/kg/min, p = 0.005). - **Relationship between intermuscular fat and exercise capacity**: After adjusting for multiple confounding factors, the ratio of intermuscular fat to skeletal muscle (IMF:SM) was negatively correlated with peak exercise capacity (p < 0.001 to 0.08). ### Conclusions - **Role of intermuscular fat**: In cancer survivors, the increase in intermuscular fat is related to the decline in peak exercise capacity, even after considering the influence of cardiac function. - **Clinical significance**: This finding indicates that intermuscular fat may be one of the important factors leading to the decline in exercise endurance of cancer survivors, suggesting that future research should focus on the changes in intermuscular fat and its impact on exercise capacity. Through these research results, the author hopes to provide a new perspective for understanding the mechanism of the decline in exercise capacity after cancer treatment and provide a scientific basis for the development of targeted intervention measures.

Increased skeletal intermuscular fat is associated with reduced exercise capacity in cancer survivors: a cross-sectional study

Both intermuscular fat and LVEF decline promote heart failure symptoms in cancer survivors

Cardiac and skeletal muscle predictors of impaired cardiorespiratory fitness post-anthracycline chemotherapy for breast cancer

Clinical, Echocardiographic, and Biomarker Associations With Impaired Cardiorespiratory Fitness Early After HER2-Targeted Breast Cancer Therapy

Intermuscular Fat Changes Are Related to Reduced Left Ventricular Ejection Fraction During Cancer Therapy (PREVENT-WF-98213)

The relationship between body composition and left ventricular performance in women with breast, lymphoma, or sarcoma cancer

Traditional markers of cardiac toxicity fail to detect marked reductions in cardiorespiratory fitness among cancer patients undergoing anti-cancer treatment

Associations between exercise capacity, p16INK4a expression and inflammation among adult survivors of childhood cancer

High intramuscular adipose tissue content associated with prognosis and postoperative complications of cancers

Exploring the links of skeletal muscle mitochondrial oxidative capacity, physical functionality, and mental well-being of cancer survivors

Metabolic Syndrome, Exercise, and Cardiovascular Fitness in Breast Cancer Survivors

Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112

Quality of muscle in the thigh predicts the prognosis in patients with non-ischemic cardiomyopathy

Abstract 2238: Reducing cardiovascular disease risk in cancer survivors: Impact of a 16-week circuit-based interval exercise intervention

Reduced Thoracic Skeletal Muscle Size is Associated with Adverse Outcomes in Diabetes Patients with Heart Failure and Reduced Ejection Fraction: Quantitative Analysis of Sarcopenia by Using Cardiac MRI

Associations of Total Body Fat Mass and Skeletal Muscle Index with All-Cause and Cancer-Specific Mortality in Cancer Survivors

CT-derived body composition: Differential association with disease, age and inflammation in a retrospective cohort study

Cardiorespiratory Fitness in Patients With Early-Stage Breast Cancer and Radiation Therapy-Related Fatigue: A Prospective Pilot Study

Intermuscular fat density as a novel prognostic factor in breast cancer patients treated with adjuvant chemotherapy

Fat-free Muscle Index Predicts Overall Survival in Mass-forming Intrahepatic Cholangiocarcinoma Patients: A Sex-stratified Analysis

Adipose tissue inflammation in breast cancer survivors: effects of a 16-week combined aerobic and resistance exercise training intervention